Evaluating the repurposing potential of the anti‐depressant Agomelatine for Alzheimer’s Disease
Grace A Terry, Michelle Merav, Patricia Rockwell, Peter Serrano, Lei Xie, Maria Figueiredo‐Pereira · 2025
Read Evaluating the repurposing potential of the anti‐depressant Agomelatine for Alzheimer’s Disease by Grace A Terry, Michelle Merav, Patricia Rockwell, Peter Serrano, Lei Xie, Maria Figueiredo‐Pereira (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11709824.txt.
Description
Grace Terry and co-authors test whether a depression drug might be reused against Alzheimer's disease. Agomelatine, an atypical antidepressant, surfaced from a screening algorithm as a candidate. It boosts melatonin receptors and blocks one serotonin receptor. Their 2025 paper tries the drug in rats bred to develop Alzheimer-like disease.
The rats carry human mutant genes that drive plaque buildup and steady mental decline with age. Treatment began at five months, before symptoms, at about ten milligrams per kilogram daily, and ran to eleven months. The team then tested the rats on a place-avoidance task, measured plaque in brain tissue, and read gene activity. Treated females showed smaller mental deficits, the abstract reports, with the tissue and gene results examined alongside. The study weighs a known drug's promise for a disease short on options.
Catalog record
| CREATOR | Grace A Terry, Michelle Merav, Patricia Rockwell, Peter Serrano, Lei Xie, Maria Figueiredo‐Pereira |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |